The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Pharmacological Characterization of Recombinant Human Neuronal Nicotinic Acetylcholine Receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 Expressed in Xenopus Oocytes
Abstract
Human neuronal nicotinic acetylcholine receptors (nAChRs) ha2b2, ha2b4, ha3b2, ha3b4, ha4b2, ha4b4 and ha7 were expressed in Xenopus oocytes and tested for their sensitivities to the nicotinic agonists acetylcholine (ACh), nicotine, cytisine (CYT) and 1,1-dimethyl-4-phenylpiperazinium (DMPP) and the nAChR. antagonists mecamylamine (MEC), d-tubocurarine and dihydro-b-erythroidine. CYT was the least efficacious agonist at hnAChRs containing b2 subunits, but it displayed significant activity at ha2b4, ha3b4, ha4b4 and ha7 nAChRs. ACh was one of the most efficacious agonists at all hnAChRs, except at ha3b2, where DMPP was markedly more efficacious than ACh. ACh was among the least potent agonists at all hnAChRs. The rank order of potency displayed by ha3b2 and ha3b4 nAChRs (DMPP'CYT'nicotine.ACh and DMPP . CYT'nicotine.ACh, respectively), differs from that reported for their rat homologs (Luetje and Patrick, 1991; Covernton et al., 1994). The agonist profile observed in ha7 also differs from that reported for its rat homolog (Seguela et al., 1993). Human a4b2 and ha4b4 nAChRs were more sensitive to dihydro-berythroidine than d-tubocurarine, whereas ha7 and ha3b4 were more sensitive to d-tubocurarine than dihydro-b-erythroidine. These antagonists were equipotent at ha2b2, ha3b2 and ha2b4 nAChRs. MEC (3 mM) inhibited ha2b4 and ha4b4 nAChRs by . 80%, whereas ha2b2, ha4b2 and ha7 nAChRs were inhibited by approximately 50%. Taken together, the differential sensitivities observed at various recombinant hnAChR subtypes indicate that both a and b subunits contribute to the pharmacology of these ligand-gated channels. The unique selectivity profiles displayed by human nAChRs constitute a valuable tool for the development of selective nicotinic analogs as potential therapeutic drugs. nAChRs are ligand-gated ion channels activated by the neurotransmitter ACh and are distributed throughout the peripheral and central nervous system (Clarke et al., 1985; Wada et al., 1989; Dineley-Miller and Patrick, 1992; Séguéla et al., 1993; Rubboli et al., 1994). To date, a gene family encoding 11 nAChR subunits has been identified (Elgoyhen et al., 1994; for a review see Sargent, 1993). We and others have cloned nine human nAChR subunits: a2, a3, a4, a5, a6, a7, b2, b3 and b4 (Elliott et al., 1996; Fornasari et al., 1990; Chini et al., 1992; Anand and Lindstrom, 1990; Tarroni et al., 1992; Doucette-Stamm et al., 1993; Peng et al., 1994; Willoughby et al., 1993). The stoichiometry of recombinant nAChRs expressed in Xenopus oocytes is thought to be (ax)2(by)3 (Anand et al., 1991; Cooper et al., 1991); however, in recombinant expression systems a7, as well as a8 and a9 can form functional homooligomeric receptors (Couturier et al., 1990; Gerzanich et al., 1994; Elgoyhen et al., 1994). Pharmacological and functional studies of recombinant rat and chicken nAChRs expressed in Xenopus oocytes have revealed a large diversity among the different subunit combinations (Luetje and Patrick, 1991; Connolly et al., 1992; see Sargent, 1993 and Papke, 1993 for review). Recent reports on the functional characterization of ha7 (Peng et al., 1994; Gopalakrishnan et al., 1995) and ha4b2 nAChRs (Gopalakrishnan et al., 1996) indicate that the human homologs are also pharmacologically and functionally diverse. Many different subtypes of nAChRs have been reported in a variety of neurons; nAChRs are present in both preand postsynaptic structures in the rodent and chick central nervous system (reviewed by Sargent, 1993 and Clarke, 1995). Received for publication April 12, 1996. ABBREVIATIONS: nAChR, neuronal nicotinic acetylcholine receptors; ACh, acetylcholine; NIC, (-)nicotine; CYT, cytisine; DMPP, 1,1-dimethyl4-phenylpiperazinium; MEC, mecamylamine; d-Tubo, d-tubocurarine; DHbE, dihydro-b-erythroidine; DRCs, dose-response curves; HEPES, N-[2-hydroxyethyl]piperazine-N9-[2-ethanesulfonic acid]. 0022-3565/97/2801-0346$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 280, No. 1 Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. JPET 280:346–356, 1997 346 at A PE T Jornals on M ay 7, 2017 jpet.asjournals.org D ow nladed from One approach to gain insight into the molecular composition of native nAChRs has been to compare their functional and pharmacological profiles with those observed using recombinant receptors. The molecular composition of some native chick and rat nAChRs has been proposed based on their pharmacological profile and the characteristics of their macroscopic currents (Mulle et al., 1991; Alkondon and Albuquerque, 1993; Covernton et al., 1994; Zhang et al., 1994). However, at the single-channel level, a good correlation has not yet been established between native and recombinant nAChRs tested to date (Connolly et al., 1995, for reviews see McGehee and Role, 1995; Sargent, 1993 and Papke, 1993). Administration of nicotinic agonists to rodents increases locomotor activity and enhances learning and memory, as shown in several behavioral tests (Clarke and Kumar, 1983; Levin et al., 1993). In human neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, there is a significant reduction in nAChR number (Rinne et al., 1991; Nordberg, 1994), and administration of nAChR agonists may ameliorate many of the motor and cognitive deficits associated with these diseases (Baron, 1986; Newhouse et al., 1988) and other motor disorders, such as Tourette’s syndrome (Moss et al., 1989). More recently, a missense mutation in the hnAChR subunit a4 was found to be associated with a form of familial frontal lobe epilepsy (Steinlein et al., 1995). Identification and characterization of the hnAChR subtypes involved in these phenomena may therefore be critical in the development of subtype-specific nAChR modulators for therapeutic purposes. Human nAChR subunits a2, a3, a4, a5, a6, a7, b2, b3 and b4 show 91–99% amino acid identity to their rat homologs in their extracellular amino terminal domain (Anand and Lindstrom, 1990; Fornasari et al., 1990; Chini et al., 1992; Doucette-Stamn et al., 1993; Willoughby et al., 1993; Peng et al., 1994; Elliott et al., 1996). These differences in the deduced amino acid sequences may affect the properties of nAChRs: substitution of a single amino acid residue in the extracellular amino terminal region of a3 (Hussy et al., 1994) and a7 (Galzi et al., 1991) nAChRs subunits has been shown to dramatically affect the pharmacology of recombinant nAChRs. Studying the properties of hnAChRs using heterologous expression may therefore provide valuable insights into the composition, function and pharmacology of native hnAChRs. We now report that, when expressed in Xenopus oocytes, recombinant hnAChRs display unique sensitivities to nAChR agonists and antagonists, and the pharmacology of some of these hnAChRs differs from that reported for their rat homologs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological Diversity of Nicotinic Acetylcholine Receptors Expressed by Vertebrate Neurons
McGehee, D. S., & Role, L. W. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.002513 · Cited by 1,022
The effects of nicotine on locomotor activity in non‐tolerant and tolerant rats
Clarke, P. B. S., & Kumar, R. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb09398.x · Cited by 457
Gopalakrishnan, M., Monteggia, L. M., Anderson, D. J., Molinari, E. J., Piattoni-Kaplan, M., Donnelly-Roberts, D., Arneric, S. P., & Sullivan, J. P. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12264-7 · Cited by 178
Cited by
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors
Nelson, M. E., Kuryatov, A., Choi, C. H., Zhou, Y., & Lindstrom, J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.332 · Cited by 422
Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 405
Moroni, M., Zwart, R., Sher, E., Cassels, B. K., & Bermudez, I. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023044 · Cited by 287
Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes
Papke, R. L., Sanberg, P. R., & Shytle, R. D. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29581-1 · Cited by 269
Metadata
- Authors
- Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1997-01
- Volume
- 280
- Issue
- 1
- Pages
- 346-356
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W4406065835
- Cited by
- 207
- References
- 3
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Characterization of Recombinant Human Neuronal Nicotinic Acetylcholine Receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 Expressed in Xenopus Oocytes. https://app.cochat.ai/papers/10.1016/s0022-3565(24)36376-1
- The paper
- Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., & Johnson, E. C. (1997). Pharmacological Characterization of Recombinant Human Neuronal Nicotinic Acetylcholine Receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 Expressed in Xenopus Oocytes. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)36376-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.